ISAPS Clinical Practice Guideline 2025: The Internationally Recognized Liquenia® Protocol
In 2025, the Liquenia-SVF protocol was included in the Clinical Practice Guideline of the International Society of Aesthetic Plastic Surgery for the management of vulvar lichen sclerosus. This page explains what that recognition means.
The organization behind the guideline
The International Society of Aesthetic Plastic Surgery (ISAPS) is the global leading scientific society in aesthetic and reconstructive surgery. It has members in over 100 countries and produces clinical practice guidelines that serve as a reference for specialists worldwide.
ISAPS Clinical Practice Guidelines are developed through a process of reviewing available evidence by a committee of international experts. For a therapeutic protocol to be included in one of these guidelines, it must meet methodological and clinical criteria evaluated independently.
Why this recognition matters
The inclusion of the Liquenia-SVF protocol in the ISAPS Clinical Practice Guideline 2025 has a specific clinical meaning: an international scientific committee, upon reviewing the available evidence, considered that the protocol meets the criteria for inclusion in clinical practice recommendations worldwide.
It is not a commercial endorsement. It is not an honorary mention. It is an independent scientific evaluation that places the Liquenia® Treatment in the same context as other internationally evaluated interventions for VLS.
For patients, it means that the protocol has not only been developed and validated by its author — it has been evaluated by experts who have no connection to its development.
For healthcare professionals, it means that the Liquenia® Treatment can be considered a therapeutic option supported by an international reference clinical guideline.
VLS in international clinical guidelines
Vulvar lichen sclerosus is the subject of specific clinical guidelines developed by leading scientific societies in dermatology and gynecology:
ISSVD Consensus Terminology 2018/2023 — reference classification and terminology BAD Guidelines for the Management of Lichen Sclerosus 2018 — British Association of Dermatologists’ management guideline EADV S2k Guideline on Lichen Sclerosus 2024 — most recent European consensus.
These guidelines establish topical corticosteroids as first-line treatment and recognize the existence of additional options for cases with insufficient response. The ISAPS 2025 guideline adds specific recognition of the Liquenia-SVF protocol as a regenerative option with published evidence.